Physician profile
James E Sellman
NPI 1225118805
$18,334.47
in general payments reported to CMS, 2019-2025
38 companies · $3,519 in 2025
The $3,519 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,109 · 2020: $1,610 · 2021: $2,523 · 2022: $2,394 · 2023: $2,998 · 2024: $3,183 · 2025: $3,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,663 · Education: $35.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,663.40 |
| Education | $35.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,478.72 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $2,296.31 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,969.07 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,285.56 | 2019-2025 | Spravato, Invega |
| Vanda Pharmaceuticals INC. | $1,077.84 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $945.77 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $822.57 | 2019-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $756.42 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $698.96 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $611.02 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Tris Pharma INC | $460.31 | 2022-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Corium, LLC | $451.15 | 2022-2025 | Azstarys, Adlarity |
| Allergan, INC. | $422.47 | 2019-2020 | |
| Neos Therapeutics, LP | $406.52 | 2020-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $359.92 | 2019-2024 | Jornay Pm |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.